SS
APGE icon

SBI Securities’s Apogee Therapeutics APGE Stock Holding History

SBI Securities’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45K Buy
26
+21
+420% +$1.89K ﹤0.01% 2340
2026
Q1 		$421 Sell
5
-1
-17% -$73 ﹤0.01% 2957
2025
Q4 		$453 Sell
6
-11
-65% -$693 ﹤0.01% 2903
2025
Q3 		$675 Buy
+17
New +$649 ﹤0.01% 2853

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

SBI Securities's APGE Position: Q2 2026 in Review

SBI Securities increased its Apogee Therapeutics (APGE) stake by 420% in Q2 2026, buying an estimated $1.89K and bringing the position to 26 shares worth $3.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

SBI Securities first reported a position in APGE in Q3 2025 and has held it in 4 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • SBI Securities held 26 shares of Apogee Therapeutics worth $3.45K as of Q2 2026.
  • SBI Securities bought 21 Apogee Therapeutics shares in Q2 2026, an estimated $1.89K.
  • Apogee Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2340 holding.
  • SBI Securities first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.